Inhibition of platelet aggregation caused by estrogen treatment in patients with carcinoma of the prostate.
Platelet aggregation is increased in patients with carcinoma of the prostate treated with estrogens. Hence, these patients have a high incidence of cardiovascular and thromboembolic diseases. Platelet aggregation has been tested with the platelet aggregation test. It was inhibited by administration of 500 mg. acetylsalicylic acid twice daily. An aggregation inhibiting effect has been found in all 38 patients. To reduce the excess hazards of cardiovascular complications of estrogens in treating carcinoma of the prostate acetylsalicylic acid is recommended as an adjunct therapy.
D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D002369:Castration; D004054:Diethylstilbestrol / Q000009:adverse effects / Q000627:therapeutic use; D004958:Estradiol / Q000009:adverse effects / Q000627:therapeutic use; D004967:Estrogens / Q000009:adverse effects*; D006801:Humans; D008297:Male; D010973:Platelet Adhesiveness / Q000187:drug effects*; D010974:Platelet Aggregation / Q000187:drug effects*; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*
D004967:Estrogens; D004958:Estradiol; D004054:Diethylstilbestrol; D001241:Aspirin